160 results on '"Salomone, Federico"'
Search Results
2. Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
3. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease
4. LBP-038 Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort
5. THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid
6. High Intake of Phenolic Acids Is Associated With Reduced Risk of Colorectal Adenomas Among Smokers
7. Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease
8. Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19]
9. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease
10. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
11. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease
12. (+)-Lipoic Acid Reduces Lipotoxicity and Regulates Mitochondrial Homeostasis and Energy Balance in an In Vitro Model of Liver Steatosis
13. De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
14. Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
15. Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease
16. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies
17. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence
18. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population
19. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease
20. High Meat Consumption Is Prospectively Associated with the Risk of Non-Alcoholic Fatty Liver Disease and Presumed Significant Fibrosis
21. SIRT5 rs12216101 T > G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD
22. Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury
23. Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C
24. Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
25. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives
26. Peripheral Insulin Resistance Predicts Liver Damage in Nondiabetic Subjects With Nonalcoholic Fatty Liver Disease
27. Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD
28. Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis
29. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease
30. Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis
31. THU-425 - De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
32. THU-415 - Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
33. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis
34. Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis
35. Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives
36. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut–liver axis
37. Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease
38. Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis
39. Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1
40. Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver
41. Coffee Consumption and Risk of Biliary Tract Cancers and Liver Cancer: A Dose–Response Meta-Analysis of Prospective Cohort Studies
42. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms
43. Molecular Bases Underlying the Hepatoprotective Effects of Coffee
44. Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease
45. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials
46. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
47. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives
48. Silibinin Protects Hepatocytes from Lipotoxicity by Inducing AMPK Phosphorylation and miRNA130a Expression
49. Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
50. Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.